Abstract:Human angiotensin-I-converting enzyme (ACE) is an important target of antihypertensive therapy, which possesses a bulky, hydrophobic pocket that is physicochemically compatible with a wide variety of peptide substrates and small-molecule ligands. Rational design of potent ACE inhibitors has long been an attractive topic in the chemical, biological and medical communities. In the present study, an integrative protocol is described to optimize and modify peptides bound with ACE based on their complex three-dimensional structures. The protocol combines a number of sophisticated computational methods including molecular dynamics (MD) simulation, quantitative structure-activity relationship (QSAR), molecular mechanics/Poisson-Boltzmann surface area (MM-PB/SA) and quantum mechanics/molecular mechanics (QM/MM) to discover new potent ACE-inhibitory peptides. With this strategy hundreds of potential peptides are generated virtually, from which several promising candidates are synthesized and assayed in vitro using a standard Fmoc-protected amino acid solid phase synthesis and spectrophotometric method, respectively. Six peptides are found to have potency against ACE, four of which (LVY, VLKP, MLPVY and LKIPLY) show satisfactory inhibitory capability (pIC(50)=5.84, 5.27, 5.40 and 5.57, respectively). Subsequently, the complex structures of tripeptide LVY and hexapeptide LKIPLY with ACE are computationally modeled and their binding free energies are estimated as -34.2 and -57.8 kcal/mol, respectively, by using a rigorous QM/MM scheme. Intensive steric collisions are observed around the C-terminus of peptide ligands in the bound state. Based upon the findings the C-terminal residues of the two peptides are modified to small, hydrophobic amino acids Val and Ala, resulting in mutated peptides LVA and LKIPVA, respectively. Consequently, a significant improvement in ACE inhibitory activity is observed for the LKIPVA mutant (pIC(50) increases from 5.57 to 6.07), whereas only a modest activity change was associated with the LVA mutant (pIC(50) decreases from 5.84 to 5.80).

Pharmacophore-based structure optimization of angiotensin converting enzyme inhibitory peptide

Angiotensin-I-converting Enzyme Inhibitory Peptides: Chemical Feature Based Pharmacophore Generation

Integrating Computational Modeling and Experimental Assay to Discover New Potent Ace-Inhibitory Peptides

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Greener liquid-phase synthesis and the ACE inhibitory structure-activity relationship of an anti-SARS octapeptide.

Molecular Mechanisms Of Several Novel Dipeptides With Angiotensin-I-Converting Enzyme Inhibitory Activity From In-Silico Screening Of Silkworm Pupae Protein

Insight into Structural Requirements of ACE Inhibitory Dipeptides: QSAR and Molecular Docking Studies

Investigation Of Angiotensin-I-Converting Enzyme (Ace) Inhibitory Tri-Peptides: A Combination Of 3d-Qsar And Molecular Docking Simulations

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Pharmacophore Model Construction of β-Secretase Inhibitors

High accuracy prediction of dipeptide angiotensin-converting enzyme (ACE) inhibitory activity by improving the credibility of the 3D-quantita- tive structure-activity relationship (3D-QSAR) model database and investigating inhibition mechanism

Optimisation and Characterisation of Novel Angiotensin-Converting Enzyme Inhibitory Peptides Prepared by Double Enzymatic Hydrolysis from Agaricus bisporus Scraps

High accuracy prediction of dipeptide angiotensin-converting enzyme (ACE) inhibitory activity by improving the credibility of the 3D-quantitative structure-activity relationship (3D-QSAR) model database and investigating inhibition mechanism

Pharmacophore model construction of beta-secretase inhibitors

Microwave-Assisted Solid-Phase Synthesis, Biological Evaluation and Molecular Docking of Angiotensin I-Converting Enzyme Inhibitors

Structural requirements of Angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship study of di- and tripeptides

Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in Vitro Evaluation.

Predictive Modeling of Angiotensin I-Converting Enzyme Inhibitory Peptides Using Various Machine Learning Approaches.

TDPBP Derivative Aiding Liquid-Phase Synthesis Strategy and ACE Inhibitory Structure-activity Relationship of Anti-SARS Octapeptide

Inhibition Mechanism and Model of an Angiotensin I-converting Enzyme (Ace)-Inhibitory Hexapeptide from Yeast (saccharomyces Cerevisiae).

Discovery of Novel Angiotensin-Converting Enzyme Inhibitory Peptides from Todarodes Pacificus and Their Inhibitory Mechanism: in Silico and in Vitro Studies